engleski

Genetic polymorphism of paraoxonase and the risk of cardiovascular diseases (CVD)

Genetic polymorphism of paraoxonase (PON1) at codon 192 (glutamine to arginine substitution, genotypes A and B, respectively) has been implicated in the risk of CVD. The aim of this study was to evaluate the distribution of PON1 polymorphism in 44 controls and 100 CVD patients with different diagnosis (coronary artery disease (CAD), myocardial infarction (MI), hypertension and carotid stenosis (CS)) by PCR-RFLP using Alw I restriction enzyme. Study results showed that out of 44 controls 40.9% were A and 2.3% B homozygotes and 56.8% heterozygotes. Among 31 CAD patients 29.0% were A and 16.1% B homozygotes and 54.8% heterozygotes. In 27 MI patients 29.6% were A and 14.8% B homozygotes and 55.6% heterozygotes. Out of 16 hypertension patients 37.5% were A and 18.8% B homozygotes and 43.8% heterozygotes. Among 26 CS patients 57.7% were A and 7.7% B homozygotes and 34.6% heterozygotes. Genotypes between controls and patients differed significantly (Chi-square test; P=0.002, 0.003, <0.001 and 0.003; for CAD, MI, Hypertension and CS patients, respectively). Allelic frequencies did not differ significantly between controls and patients. Our findings indicate that common polymorphism in the PON1 gene may be an independent risk factor for some cardiovascular diseases.

PON1; cardiovascular diseses

nije evidentirano